|
|
|
|
|
Last Trade
|
Last Trade:
$3.07
|
Change:
-0.08 (-2.54%)
|
Trade Time:
Sep 20
|
Market Cap:
$40.09M
|
|
|
|
|
|
|
Description of Business
|
|
We are a biotechnology company focused on the research and discovery of new and
effective treatments for psychiatric and neurological disorders. Epidemiological
data indicate neuropsychiatric disorders as being some of the most prevalent,
devastating, and yet poorly treated illnesses. We believe that the current
treatments for these disorders, such as depression, are inadequate and that
conventional medicines have low success rates in long-term treatment. According
to an article published by PLOS One, randomized, double-blind,
placebo-controlled clinical trials of antidepressants were only effective for
42-51% of patients with MDD. For example, current pharmacotherapies for MDD and
BDep have a distinct lag of onset that can generate further distress and
impairment in patients.
|
|
|
|